Methods: The Dutch Arthritis Foundation started its campaign on World Arthritis Day: ‘Grow awareness, plant a bulb’. To ‘grow understanding’, we created two simultaneous tulip bulb fields, one online and one offline, for participants to plant the special ‘Anita Witzier’ tulip bulb. Anita Witzier is a well-known Dutch television host who suffers from rheumatoid arthritis. She has been ambassador for the Dutch Arthritis Foundation since 2001.

With the help from 70% of all local RMD patient organisations and a number of garden centres, we handed out a total of 15 000 bags of tulip bulbs across the Netherlands. The campaign kick-off was on World Arthritis Day. The event, held on a tulip breeder’s field, hosted presentations about incomprehension, and served to share real-life stories.

We also developed a website where people could plant bulbs digitally. Every week, participants receive a video, cartoon, update or article with information about RMDs. The campaign will run until 21 May 2018 when the (real-life) tulips will bloom in our RMD field. All participants can then visit the field to pick a bunch of flowers.

Results: The campaign received a great deal of national media attention on World Arthritis Day, and featured on television programmes, in newspapers and on online platforms. 8000 people have since signed up for the online tulip field, sharing the information with others in their network. The campaign site drew 68 000 visitors between 120c and 310c tober. The campaign also resonated with people on Facebook. In October, our campaign posts reached 1,869,000 visitors, with more than 65 000 interactions (respond, share, like, watch video, conversion to campaign site).

Conclusions: Raising awareness for incomprehension can be difficult. A creative approach can help to kickstart a public debate. Responses generally show that people with RMDs appreciate this complicated subject being put on the map.

Disclosure of Interest: None declared


OP0297

DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS: PATIENTS IS INFLUENCED BY COUNTRIES' SOCIOECONOMICS: RESULTS FROM THE METEOR REGISTRY

S.A. Bernström1*, J. Tavares-Costa2, M. Garzo-Elizondo3, K. Salomon-Escoto4, N. Govind2, C. Alisar2, R. Landewe5, 1Rheumatology, LUMC, Leiden, Netherlands; 2Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal; 3Hospital Universitario Dr José Eleuterio González, Monterrey, Mexico; 4UMass Memorial Medical Center, Worcester, USA; 5University of the Witwatersrand, Johannesburg, South Africa; 6ARIC, Amsterdam, Netherlands

Background: The treatment and prognosis of rheumatoid arthritis (RA) patients have improved tremendously, but patients across the world may not benefit similarly. One of the potentially critical factors may be poorer access to expensive biologic (b)DMARDs.

Objectives: To investigate daily practice data regarding bDMARD-use in different countries worldwide and assess if a lower country’s socio-economic status (SES) is associated with worse clinical outcomes and lower usage of bDMARDs.

Methods: Data on disease activity and drug use from countries that contributed >100 RA patients after 1–1–2000 were extracted from the daily practice, observational METEOR database. Missing data were imputed using multivariate normal imputation (30-cycles). Gross domestic product (GDP) per capita in International dollars (Intl$) as indicator of SES per country average DAS28 and the proportion of patients in DAS28-remission (DAS28 < 2.6) were calculated by taking the average of all patients at the last available visit. Univariable logistic regression analyses were performed to assess associations between GDP, bDMARD use and disease outcomes at a country level.

Results: In total, 20,379 patients were included from 12 countries: United States, Mexico, South-Africa, Japan, Brazil, United Kingdom, Spain, Ireland, Portugal, France, India and the Netherlands. The number of patients ever using a bDMARD varied between 0.9% (South-Africa) and 75% (Ireland). The proportion of patients in remission at the final visit varied between 2% (India) and 39% (Netherlands).

Patients in countries with a higher GDP per capita had a lower average DAS28 and consequently, a higher proportion of them were in DAS28-remission: β (95% CI) = −0.32 (-0.41; -0.231) lower DAS28 and an additional 4.2% (0.14; 8.29) patients in DAS28-remission for every 10,000 Intl$ additional GDP.

To underscore the assumption that the association between SES and DAS28 is mediated by bDMARD use, we assessed whether SES was associated with bDMARD use per country. Indeed, a higher GDP per capita was associated with a higher proportion of patients using a bDMARD: β (95% CI) = 11.2 (4.82; 17.5), indicating an additional 11% of patients using a bDMARD per 10,000 Intl$ increase in GDP per capita. Furthermore, DAS28 was β (95% CI) = −0.14 (-0.28; −0.0054) lower and 2.8% (-0.13; 5.8) more patients achieved DAS28-remission per 10% increase in proportion of patients using a bDMARD, figure 1.

Abstract OP0297 – Table 1 Associated between ‘GDP per capita (Intl$), % bDMARD use’ and ‘disease activity’.

Conclusions: RA patients in countries with a lower SES had worse disease activity. Although patients in countries with a lower SES less often used bDMARDs, the effect of bDMARD use on disease activity was smaller than expected, indicating that other factors than access to bDMARDs may contribute to the effectiveness of RA treatment.

Disclosure of Interest: None declared


FRIDAY, 15 JUNE 2018

More money or more education and collaboration?_